MedTrace Logo

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

NCT04278118 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-02-17

No results posted yet for this study

Summary

This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.

Conditions

  • Grade I Meningioma
  • Grade II Meningioma
  • Grade III Meningioma
  • Intracranial Neoplasm
  • Nerve Sheath Neoplasm
  • Pituitary Gland Adenoma
  • Schwannoma

Interventions

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Hypofractionated Radiation Therapy

Undergo hypofractionated proton or photon radiation therapy

RADIATION

Photon Beam Radiation Therapy

Undergo hypofractionated proton or photon radiation therapy

RADIATION

Proton Beam Radiation Therapy

Undergo hypofractionated proton or photon radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Bree R Eaton · Emory University Hospital/Winship Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-18
Primary Completion
2030-12-01
Completion
2031-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04278118 on ClinicalTrials.gov